The COVID-19 Pandemic and Its Influence on Patients With Myotonic Dystrophy Type 1: Lessons Learned.

Autor: Kleinveld VEA; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Bruijnes JE; Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, the Netherlands., Labrecque S; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Jeurissen-Bekkering DEG; Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, the Netherlands., Faber CG; Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, the Netherlands., Horlings CGC; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.; Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Jazyk: angličtina
Zdroj: Brain and behavior [Brain Behav] 2024 Nov; Vol. 14 (11), pp. e70162.
DOI: 10.1002/brb3.70162
Abstrakt: Introduction: Myotonic dystrophy type 1 (DM1) patients might represent a high-risk population for severe COVID-19 disease, as cardiopulmonary symptoms are part of the clinical spectrum of DM1. The COVID-19 pandemic may have impacted DM1 patients. We aimed to determine the effect of the COVID-19 pandemic on DM1 patients to guide management strategies in possible future pandemics.
Methods: Data on the presence of a COVID-19 infection were retrieved from 195 DM1 patients in the MYODRAFT database. Between August 12 and October 4, 2021, 82 patients and proxies filled out a questionnaire on COVID-19 symptoms, well-being, and organization of care. Data were compared to prepandemic data.
Results: A total of 18 patients had COVID-19 (13 confirmed, 5 probable infections). The prevalence of COVID-19 in our cohort was 9.2%, which was lower than in the Dutch population (11.5%). Four patients (22.2%) were hospitalized due to a COVID-19 infection, which was higher than in the Dutch population (3.6%). Two infected patients died. A high rate of canceled appointments was reported. Patients reported no change in physical functioning during the pandemic, whereas proxies reported a deterioration in mental and physical well-being of patients.
Conclusions: The prevalence of COVID-19 infections was not higher in DM1 patients than in the general population, but DM1 patients are more susceptible to complicated disease when infected. Longitudinal data on patient-reported physical functioning suggest that the COVID-19 pandemic and the pandemic management strategies implemented did not influence the course of disease in DM1 patients, and similar strategies can be re-used in comparable situations.
(© 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje